TrialAnnals of surgical oncology2023

Three-Course Neoadjuvant Chemotherapy Associated with Unfavorable Survival of Non-responders to the First Two Courses for Locally Advanced Esophageal Cancer.

Yuto Kubo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.